Factor exposure
Growth tilted with a strong quality bias.
H143 Research Intelligence
Research before
conviction.
A systematic framework for separating narrative from durable compounding—combining growth, financial health, expectations and valuation.
Independent publicationPrimary-source researchNo client accounts or outside capital
Our research methodology →
Editorial standard
Research begins with issuer filings, earnings materials and clearly identified assumptions. Conclusions remain open to revision when the evidence, valuation or risk profile changes.
Personal portfolio intelligence
Growth × financial health
Lower healthFinancial healthHigher health
GrowthValue
Growth-ledBalancedValue-led
METAMeta Platforms
01 / 10AMetricAssessmentSignal
Directional H143 research signals—not live financial data or price targets. Refresh after filings and material guidance changes.
Research insights
Evidence over narrative
Earnings revisions
Track estimate direction after every reported quarter.
Valuation discipline
Test the thesis across multiples, DCF and downside cases.
Research philosophy
Growth, disciplined by financial reality.
H143 studies durable growth where balance-sheet strength, improving economics and a rational valuation may create a credible path to long-term compounding.
Business quality
Competitive position, customer retention, pricing power and management execution.
Financial health
Liquidity, leverage, EBITDA quality, free cash flow and dilution discipline.
Expectations
Revenue and earnings revisions, guidance credibility and catalyst visibility.
Valuation
PEG, P/E, PVG composite, DCF, book value and EV/EBITDA where applicable.
Personal portfolio disclosure
Hari Patel's disclosed positions.
This website portfolio is not an up-to-date live portfolio. H143 Capital Research updates the public portfolio section once a month; current portfolio changes and trade updates are shared through the paid Substack. This is not a recommendation, model portfolio or invitation to follow the same holdings. Paid Substack / @h143capital · X / @H143capital
Equity positions
Defined-risk options spreads
Scoring methodology
A matrix designed to be challenged.
Each company is assessed on consistent evidence. Scores are qualitative research inputs—not forecasts—and should be refreshed after earnings, guidance changes or material company events.
Growth
Revenue runway, market expansion, backlog, retention and operating leverage.
Financial health
Cash, leverage, free cash flow, EBITDA quality, dilution and capital intensity.
Expectations
Consensus revisions, guidance, estimate dispersion and catalyst timing.
Valuation
PEG, P/E, PVG composite, DCF, book value per share and EV/EBITDA.
Data standard
Financial statements and company guidance should come from the latest issuer filings and earnings materials. Analyst expectations and valuation inputs should be timestamped and sourced before public display. Biotech and pre-profit companies require pipeline-adjusted measures because conventional P/E or EBITDA may not be meaningful.
Research journal
Ideas in progress.
Company notes, watchlist research and long-term perspectives—organized in a dedicated research journal.
RESEARCH NOTE 08 · SUJA
Suja Life
It’s not possible, it’s necessary: a cautious Buy framework around Q2 earnings, revised guidance, wellness-category growth and valuation.
Read research note →RESEARCH NOTE 07 · SAROStandardAero
I can do this all day: a cautious Buy framework around aerospace MRO, Q2 earnings quality, LEAP/CFM56 growth and balance-sheet risks.
Read research note →RESEARCH NOTE 06 · HONAHoneywell Aerospace
A small bite of an undercooked steak: a cautious buy framework after HONA's Q2 guidance reset, supply-chain miss and valuation discount.
Read research note →RESEARCH NOTE 05 · TSX/NYSE: STNStantec
Priced for trouble, built for resilience: a small-starter thesis around infrastructure demand, Page synergies, Q2 expectations and balance-sheet discipline.
Read research note →RESEARCH NOTE 04 · NYSE: ORCLOracle
The Iron Throne of AI comes with a heavy debt burden: capex, backlog, bond-market pressure and the risks behind Oracle’s AI strategy.
Read research note →RESEARCH NOTE 03 · TSX/NYSE: MDAMDA Space
Built for wanderers, bound for the stars: a cautious Buy framework for MDA Space after its recent reset.
Read research note →RESEARCH NOTE 02 · NASDAQ: ADSKAutodesk
Choosing plata while the market reaches for plomo: a personal long thesis on Autodesk after the MaintainX acquisition reset.
Read research note →RESEARCH NOTE 01 · NASDAQ: FLYFirefly Aerospace
Contract momentum, lunar execution and the risks embedded in an ambitious space platform.
Read research note →